HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis

Abstract

In women, estrogen deficiency after menopause frequently accelerates osteoclastic bone resorption, leading to osteoporosis, the most common skeletal disorder. However, mechanisms underlying osteoporosis resulting from estrogen deficiency remain largely unknown. Here we show that in bone-resorbing osteoclasts, estrogendependent destabilization of hypoxia-inducible factor 1 alpha (HIF1α), which is unstable in the presence of oxygen, plays a pivotal role in promoting bone loss in estrogen-deficient conditions. In vitro, HIF1α was destabilized by estrogen treatment even in hypoxic conditions, and estrogen loss in ovariectomized (Ovx) mice stabilized HIF1α in osteoclasts and promoted their activation and subsequent bone loss in vivo. Osteoclast-specific HIF1α inactivation antagonized bone loss in Ovx mice and osteoclast-specific estrogen receptor alpha deficient mice, both models of estrogen-deficient osteoporosis. Oral administration of a HIF1α inhibitor protected Ovx mice from osteoclast activation and bone loss. Thus, HIF1α represents a promising therapeutic target in osteoporosis.B one mass is tightly regulated by a delicate balance between osteoblastic bone formation and osteoclastic bone resorption. Estrogen loss in women after menopause frequently promotes activation of osteoclastic bone resorption, causing osteoporosis. Osteoporotic bone phenotypes are seen in ovariectomized female mice, and estrogen deficiency-induced bone loss in both mouse models and women is ameliorated by estrogen treatment (1, 2). However, estrogen administration reportedly increases risk of cardiovascular events and carcinogenesis of the mammary gland and uterus (3). Bioavailable estrogens including selective estrogen receptor modulators (SERMs) also protect bone from estrogen deficiency-induced osteoporosis (4), and estrogen and SERMs primarily act via estrogen receptors (ER), ERα and ERβ (5, 6). However, how SERMs act on bone remains largely unknown. Thus, understanding of osteoclast activation following estrogen loss is crucial for development of safe therapeutic reagents.Both the endosteal zone of bone marrow cavities and epiphyseal growth plates are hypoxic areas, and the hypoxia-inducible factor (HIF) signaling pathway governs chondrocyte and osteoblast function in these respective areas (7,8). The HIF1 transcription factor consists of an oxygen-regulated alpha subunit, HIF1α, and a constitutively expressed beta subunit, HIF1β. Under normoxia, HIF1α is posttranslationally modified by prolyl hydroxylases, which catalyze hydroxylation of proline residues in the presence of O 2 and Fe 2+ . Recognition of hydroxylated HIF1α by the von Hippel-Lindau tumor suppressor protein recruits an E3 ubiquitin ligase complex targeting HIF1α for proteasomal degradation. Conversely, under hypoxia, proline hydroxylation is inhibited by substrate (O 2 ) deprivation, allowing HIF1α accumulation and formation of an active transcriptional complex with HIF1β (9). Recently, regulation of HIF1α protein levels by factors other than O 2 , including reactive ...

Estrogens maintain skeletal muscle and satellite cell functions

“…A recent study has reported that HIF1α is a crucial factor in the activation of osteoclasts that promote bone resorption after menopausal estrogen insufficiency. Indeed, estrogens prevent HIF1α activation, leading to the suppression of osteoclast activity (Miyauchi et al 2013). Nuclear factor-κB (NF-κB), a transcription factor of inflammatory genes, induces muscle atrophy, along with the loss of slow-twitch fibers (Li et al 2008, Wang & Pessin 2013.…”

Tectorigenin inhibits RANKL‐induced osteoclastogenesis via suppression of NF‐κB signalling and decreases bone loss in ovariectomized C57BL/6

“…The reduction of oestrogen levels is related to the development of postmenopausal osteoporosis in female populations 5, 21. This study simulates menopause by removing the ovaries in female C57BL/6 mice, resulting in postmenopausal osteoporosis.…”

How much medium do you use for cell culture? Medium volume influences mineralization and osteoclastogenesis in vitro

“…Furthermore, osteoclastogenesis appears to be accelerated by increasing volumes of culture medium and a concomitant increase in nutrients, including glucose (3,5). Glucose was the principal energy source required for bone degradation (29), and hypoxia-inducible factor 1 alpha was stabilized in osteoclasts, leading to osteoclast activation (30). This suggests that the differentiation of large multinuclear osteoclasts may be influenced by the glucose content, and also by low concentrations of oxygen in the medium (6,7).…”